Ashkon Software

   







 


OHRP - Ohr Pharmaceuticals, Inc.

Ohr Pharmaceuticals, Inc. logoOhr Pharmaceuticals, Inc. (OHRP) is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of ophthalmic diseases. The company's lead product candidate is squalamine lactate ophthalmic solution, which is being developed as a treatment for retinal diseases such as wet age-related macular degeneration (AMD). Here's an extended company report for Ohr Pharmaceuticals, Inc.:

Ohr Pharmaceuticals, Inc. was founded in 2008 and is headquartered in New York City. The company's core focus is on developing and commercializing novel therapies for the treatment of ophthalmic diseases. OHRP's lead product candidate, squalamine lactate ophthalmic solution, is being developed as a treatment for retinal diseases such as wet AMD, which is the leading cause of blindness in people over the age of 65.

Squalamine lactate ophthalmic solution is a novel therapeutic agent that works by inhibiting the growth of abnormal blood vessels in the retina, which is a key factor in the development of wet AMD. The drug has been granted fast-track status by the U.S. Food and Drug Administration (FDA) and is currently in phase 3 clinical trials.

In addition to its lead product candidate, Ohr Pharmaceuticals has a pipeline of other drug candidates for the treatment of various ophthalmic diseases, including glaucoma and diabetic retinopathy. The company's diverse pipeline of products allows it to serve a wide range of patients with unmet medical needs.

As of March 18, 2023, Ohr Pharmaceuticals had a market capitalization of approximately $10 million. The company's stock is traded on the NASDAQ exchange under the ticker symbol OHRP.

Investing in Ohr Pharmaceuticals involves significant risks, including the risk that the company's products may not gain regulatory approval, the risk of increased competition from other companies in the ophthalmic drug space, and the risk of adverse side effects associated with the use of the company's products.

In conclusion, Ohr Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of ophthalmic diseases. The company's lead product candidate, squalamine lactate ophthalmic solution, is being developed as a treatment for wet AMD and has been granted fast-track status by the FDA. Ohr Pharmaceuticals' diverse pipeline of products allows it to serve a wide range of patients with unmet medical needs. Investors should carefully consider the risks and potential benefits of investing in Ohr Pharmaceuticals before making any investment decisions.

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer